| Zeit | Aktuelle Nachrichten
| | Leser | Medien |
|---|
| 09.02.
| Charting Vical's Latest Earnings Release | | 6 | Motley Fool |
| 09.02.
| Vical's Herpes Vaccine Headed To The Clinic | | 4 | Seeking Alpha |
| 08.02.
| Vical's CEO Discusses Q4 2011 Results - Earnings Call Transcript | | 6 | Seeking Alpha |
| 08.02.
| Hot Stock: Vical, Shares Drop 6.1% | | 4 | SmarTrend |
| 08.02.
| Notable Call Options Activity in Vical | | 7 | Benzinga.com |
| 03.02.
| Vical Inc.: A $3 Biotech Lottery Ticket I Am Buying Now | | 27 | Seeking Alpha |
| 31.01.
| Vical's Allovectin: If Approved, What Kind Of Launch Can Be Expected? | | 20 | Seeking Alpha |
| 30.01.
| Vical Presents Case Study on Successful Design of Allovectin Phase 3 Melanoma Trial | | 14 | Benzinga.com |
| 06.01.
| Investors look to Lighten Up on Shares of Vical, Shares Down 11.7% | | 7 | SmarTrend |
| 06.01.
| Rodman & Renshaw, LLC Acts as a Co-Manager to Vical Incorporated in Public Offering of Common Stock | | 55 | Business Wire |
| Rodman & Renshaw, LLC, a wholly owned subsidiary of Rodman &
Renshaw Capital Group, Inc. (NASDAQ: RODM) announced that it has acted
as a Co-Manager to its client Vical...
Mehr lesen zu:
Rodman & Renshaw, LLC Acts as a Co-Manager to Vical Incorporated in Public Offering of Common Stock | |
| 06.01.
| Vical (VICL) Prices 13.3M Offering at 12.5% Discount | | 5 | StreetInsider.com |
| 06.01.
| Vical Incorporated Prices Public Offering of Common Stock at $3.75 per Share | | 5 | Benzinga.com |
| 05.01.
| Vical Incorporated (Nasdaq:VICL) today announced that it intends to offer and sell shares of its common stock in an underwritten public offering. Citigroup, Credit Suisse Securities (USA) LLC and Leerink Swann LLC are acting as joint book-running managers | | 9 | Benzinga.com |
| 05.01.
| Vical Incorporated Announces Proposed Public Offering of Common Stock; No Size Given | | 4 | Benzinga.com |
| 23.11.
| Dynavax and Vical -- Undervalued and Gaining Attention / The Bedford Report Provides Equity Research on Dynavax & Vical | | 54 | MarketWire |
| NEW YORK, NY -- (Marketwire) -- 11/23/11 -- Despite disappointing third quarter results for some of biotechnology's up-and-coming stars, there is plenty of optimism in the industry. According to Lipper...
Mehr lesen zu:
Dynavax and Vical -- Undervalued and Gaining Attention / The Bedford Report Provides Equity Research on Dynavax & Vical | |
| 04.11.
| VICAL INC - 10-Q, Quarterly Report | | 10 | SEC Filings |
| 22.09.
| Global Situation & Resulting Influences - Research Report on Vical Incorporated and Life Technologies Corp. | | 21 | MarketWire |
| MACAU -- (Marketwire) -- 09/22/11 -- Today, www.EquityMarketsInc.com announced its research report highlighting Vical Incorporated (NASDAQ: VICL) and Life Technologies Corp. (NASDAQ: LIFE). Full content...
Mehr lesen zu:
Global Situation & Resulting Influences - Research Report on Vical Incorporated and Life Technologies Corp. | |
| 22.09.
| Vical Inc. (VICL) Announces Encouraging Data Using Combination of Allovectin With Anti-CTLA-4 Antibody | | 11 | StreetInsider.com |
| 22.09.
| Vical (VICL) Reports Encouraging Data from Allovectin and anti-CTLA-4 Antibody Study | | 10 | StreetInsider.com |
